BioNTech SE (BNTX) Capital Expenditures (2018 - 2025)

BioNTech SE has disclosed Capital Expenditures across 8 years of filings, most recently posting -$73.6 million for Q4 2025.

• Capital Expenditures for Q4 2025 came in at -$73.6 million, down 3.37% year-over-year; the trailing twelve-month figure through Dec 2025 was -$197.6 million (up 36.26% YoY), and the FY2025 annual result was -$197.8 million, up 35.38% from the prior year.
• Capital Expenditures came in at -$73.6 million for Q4 2025 at BioNTech SE, down from -$42.0 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of -$26.18 in Q1 2021 to a low of -$139.4 million in Q4 2022.
• The 5-year median for Capital Expenditures is -$67.4 million (2024), against an average of -$65.0 million.
• Across the five-year window, Capital Expenditures soared 100.0% in 2021 and tumbled 189090564.66% in 2022, its largest moves.
• BioNTech SE's Capital Expenditures stood at -$45.1 million in 2021, then plunged by 209.2% to -$139.4 million in 2022, then surged by 35.3% to -$90.2 million in 2023, then climbed by 21.07% to -$71.2 million in 2024, then decreased by 3.37% to -$73.6 million in 2025.
• The last three Capital Expenditures figures came in at -$73.6 million (Q4 2025), -$42.0 million (Q3 2025), and -$30.7 million (Q2 2025), per Business Quant data.